Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TerbinaPro: Terbinafine for Biochemically Recurrent Prostate Cancer
NCT07365423Phase 2Recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Terbinafine in recurrent prostate cancer (RPC), sponsored by Swiss Group for Clinical Cancer Research. Started Apr 2026; status: recruiting.
02
Drugs
Terbinafine
03
Conditions
recurrent prostate cancer (RPC)
Beyond the preview
Go deeper on NCT07365423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365423.